Your browser doesn't support javascript.
Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19.
Tran, Florian; Harris, Danielle M M; Scharmacher, Alena; Graßhoff, Hanna; Sterner, Kristina; Schinke, Susanne; Käding, Nadja; Humrich, Jens Y; Cabral-Marques, Otávio; Bernardes, Joana P; Mishra, Neha; Bahmer, Thomas; Franzenburg, Jeanette; Hoyer, Bimba F; Glück, Andreas; Guggeis, Martina; Ossysek, Alexander; Küller, Andre; Frank, Derk; Lange, Christoph; Rupp, Jan; Heyckendorf, Jan; Gaede, Karoline I; Amital, Howard; Rosenstiel, Philip; Shoenfeld, Yehuda; Halpert, Gilad; Rosenberg, Avi Z; Schulze-Forster, Kai; Heidecke, Harald; Riemekasten, Gabriela; Schreiber, Stefan.
  • Tran F; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Harris DMM; Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Scharmacher A; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Graßhoff H; Institute for Human Nutrition and Food Science, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Sterner K; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Schinke S; Department of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
  • Käding N; Department of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
  • Humrich JY; Department of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
  • Cabral-Marques O; Department of Infectious Diseases and Microbiology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
  • Bernardes JP; Department of Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein, Lübeck, Germany.
  • Mishra N; Department of Immunology, Instituto de Ciencias Biomedicas, Universidade de São Paulo, São Paulo, SP, Brazil.
  • Bahmer T; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, SP, Brazil.
  • Franzenburg J; Network of Immunity in Infection, Malignancy, and Autoimmunity, Universal Scientific Education and Research Network, Sao Paulo, SP, Brazil.
  • Hoyer BF; Department of Medicine, Division of Molecular Medicine, University of São Paulo School of Medicine, São Paulo, Brazil.
  • Glück A; Laboratory of Medical Investigation 29, University of São Paulo School of Medicine, São Paulo, Brazil.
  • Guggeis M; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Ossysek A; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Küller A; Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Frank D; LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany.
  • Lange C; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Rupp J; Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Heyckendorf J; Section for Rheumatology, Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Gaede KI; Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Amital H; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Rosenstiel P; Department of Internal Medicine I, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Shoenfeld Y; Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Halpert G; Department of Internal Medicine III, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Rosenberg AZ; Department of Internal Medicine III, University Medical Center Schleswig-Holstein, Kiel, Germany.
  • Schulze-Forster K; German Centre for Cardiovascular Research (DZHK), partner site Hamburg, Kiel, Lübeck, Germany.
  • Heidecke H; Research Center Borstel, Borstel, Germany.
  • Riemekasten G; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Borstel, Germany.
  • Schreiber S; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany.
ERJ Open Res ; 8(4)2022 Oct.
Article in English | MEDLINE | ID: covidwho-2196020
ABSTRACT
In patients with severe #COVID19, increased levels of autoantibodies against PAR1 were found. These might serve as allosteric agonists of PAR1 on endothelial cells and platelets, and thus might contribute to the pathogenesis of microthrombosis in COVID-19. https//bit.ly/3pqM9Vv.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Risk_factors_studies Language: English Year: 2022 Document Type: Article Affiliation country: 23120541.00379-2022

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Risk_factors_studies Language: English Year: 2022 Document Type: Article Affiliation country: 23120541.00379-2022